Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Fluarix/Influsplit Tetra (2013/2014 Season) in Adults 18 Years of Age and Older
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- 22 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jul 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-001094-25).